TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21169874

Group type: EXPERIMENTAL
Intervention: Lacto‐Wolfberry (LWB) 13.7 g/d for 90 days
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 18349190

Group type: EXPERIMENTAL
Intervention: Vibrotactile display group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (standard monitoring alone)
Number of subjects: 24
Study: 16600227

Group type: EXPERIMENTAL
Intervention: Medium buffered with HEPES
Number of subjects: 708

Group type: COMPARATOR
Intervention: Medium buffered without HEPES
Number of subjects: 708
Study: 14637332

Group type: EXPERIMENTAL
Intervention: Cereal (Cheerios or Shreddies)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Glucose drink
Number of subjects: 29

Group type: COMPARATOR
Intervention: No breakfast
Number of subjects: 29
Study: 10627328

Group type: EXPERIMENTAL
Intervention: Arm-support in healthy subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: No arm-support in healthy subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of quadriceps in paraplegic patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: No electrical stimulation in paraplegic patients
Number of subjects: 0
Study: 9177507

Group type: EXPERIMENTAL
Intervention: Acid infusion (0.1 N HCl at 6-8 cc/min)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Saline infusion (0.9 N saline)
Number of subjects: 21
Study: 8247818

Group type: EXPERIMENTAL
Intervention: Activity protocol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Bed rest
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cardiovascular fitness
Number of subjects: 15
Study: 2859047

Group type: EXPERIMENTAL
Intervention: Ro31-1118 (10 mg orally)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ro31-1118 (20 mg orally and intravenously)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ro31-1118 (40, 80, 160, and 320 mg orally)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ro31-1118 (320 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ro31-1118 (not specified dose)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Atenolol (100 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Atenolol (50 mg)
Number of subjects: 16
Study: 31444861

Group type: EXPERIMENTAL
Intervention: Resilient hyaluronic acid dermal filler
Number of subjects: 140

Group type: COMPARATOR
Intervention: Comparator filler
Number of subjects: 140
Study: 28759275

Group type: EXPERIMENTAL
Intervention: Subjects with depressive symptoms (CES-D score ≥ 16)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Subjects without depressive symptoms (CES-D < 16)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Non-white subjects
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Lung function (FEV1%) and asthma control
Number of subjects: 599
Study: 26956551

Group type: EXPERIMENTAL
Intervention: Testosterone pretreatment (10 mg transdermal gel for 21 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No pretreatment
Number of subjects: 50
Study: 24168317

Group type: EXPERIMENTAL
Intervention: Remote monitoring with the Dexcom G4 PLATINUM communicating with the Diabetes Assistant
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual wear of a Dexcom G4 PLATINUM CGM system
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Remote monitoring
Number of subjects: 20
Study: 23152846

Group type: EXPERIMENTAL
Intervention: Ginger preparation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 20186829

Group type: EXPERIMENTAL
Intervention: High-dose ghrelin (13 microg/kg daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Low-dose ghrelin (0.7 microg/kg daily)
Number of subjects: 31
Study: 17595201

Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Oral Amoxicillin
Number of subjects: 425

Group type: COMPARATOR
Intervention: HIV-1 infected children <12 months
Number of subjects: 425

Group type: COMPARATOR
Intervention: HIV-1 infected children
Number of subjects: 425

Group type: COMPARATOR
Intervention: HIV exposed uninfected children
Number of subjects: 425
Study: 16327738

Group type: EXPERIMENTAL
Intervention: Self-administration of the EORTC QLQ-SAT32 questionnaire
Number of subjects: 123

Group type: COMPARATOR
Intervention: Interview administration of the EORTC QLQ-SAT32 questionnaire
Number of subjects: 123
Study: 11926620

Group type: EXPERIMENTAL
Intervention: Grapeseed extract (GSE) 100 mg, twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9927239

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7653811

Group type: EXPERIMENTAL
Intervention: Acetaminophen with codeine (1 mg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Acetaminophen (15 mg/kg)
Number of subjects: 50
Study: 2519572

Group type: EXPERIMENTAL
Intervention: Buserelin-hMG
Number of subjects: 35

Group type: COMPARATOR
Intervention: FSH-hMG
Number of subjects: 35
Study: 28719078

Group type: EXPERIMENTAL
Intervention: Luseogliflozin (2.5 mg, newly administered)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Metformin (1500 mg, newly or additionally administrated)
Number of subjects: 32
Study: 26849997

Group type: EXPERIMENTAL
Intervention: LSD (200 μg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 24908387

Group type: EXPERIMENTAL
Intervention: Voluntary transition to oral methadone
Number of subjects: 95
Study: 23652909

Group type: EXPERIMENTAL
Intervention: Isotretinoin 20 mg orally once daily for 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo therapy (glucose capsules) for 3 months after isotretinoin therapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isotretinoin therapy
Number of subjects: 30
Study: 20053975

Group type: EXPERIMENTAL
Intervention: Aqueous humor from RP patients
Number of subjects: 15

Group type: COMPARATOR
Intervention: Aqueous humor from control group (patients undergoing cataract surgery)
Number of subjects: 15
Study: 18428023

Group type: EXPERIMENTAL
Intervention: Acute insulin response (AIR)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Sensitivity index (S(I))
Number of subjects: 171
Study: 16132058

Group type: EXPERIMENTAL
Intervention: 250 ml/day of Sicilian red wine for 4 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual wine intake for 4 weeks
Number of subjects: 48
Study: 12972981

Group type: EXPERIMENTAL
Intervention: 50 pulses per second (PPS; n=13)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 200 pulses per second (PPS; n=11)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (50 PPS and 200 PPS)
Number of subjects: 24
Study: 10838463

Group type: COMPARATOR
Intervention: Hypocaloric diet alone (80% of predicted needs)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet + resistance exercise + casein protein (1.5 g/kg/day)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet + resistance exercise + whey protein hydrolysate
Number of subjects: 38
Study: 9349888

Group type: EXPERIMENTAL
Intervention: Partial resection of the first annular pulley
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard complete first annular pulley release
Number of subjects: 19
Study: 8251808

Group type: EXPERIMENTAL
Intervention: Retinyl palmitate
Number of subjects: 510

Group type: COMPARATOR
Intervention: Beta carotene
Number of subjects: 510
Study: 3102375

Group type: EXPERIMENTAL
Intervention: Physiotherapy with ultrasound
Number of subjects: 154

Group type: COMPARATOR
Intervention: Physiotherapy without ultrasound
Number of subjects: 154
Study: 30633580

Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplements (ONS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no ONS)
Number of subjects: 100
Study: 27351629

Group type: EXPERIMENTAL
Intervention: Saccade training (experimental)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Reading training (control)
Number of subjects: 25
Study: 23834666

Group type: EXPERIMENTAL
Intervention: BAX326 (recombinant factor IX); Dosage: 49.5 (±4.8) IU kg(‐1) per infusion, administered twice weekly for a mean duration of 6.2 (±0.7) months
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: BAX326 (recombinant factor IX); used for controlling acute bleeds
Number of subjects: 73

Group type: COMPARATOR
Intervention: Historical control group (on-demand treatment)
Number of subjects: 73
Study: 21764558

Group type: EXPERIMENTAL
Intervention: SF-36 questionnaire
Number of subjects: 120
Study: 20070299

Group type: EXPERIMENTAL
Intervention: 1-year maintenance after a 6-week cycle of early intravesical chemotherapy (epirubicin, 80 mg/50 mL)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Control group (6-week induction cycle only)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Maintenance regimen with monthly instillations for 1 year
Number of subjects: 482
Study: 17445330

Group type: EXPERIMENTAL
Intervention: Outreach intervention for providers and CBD agents
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Detailing intervention
Number of subjects: 45

Group type: COMPARATOR
Intervention: Current standard of care (DMPA)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Provider-based activities with concurrent demand creation activities
Number of subjects: 45
Study: 16199428

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 35 mg/cyproterone acetate 2 mg (EE/CPA: 21/28 days cycle)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combined treatment of rosiglitazone and EE/CPA
Number of subjects: 28
Study: 12955342

Group type: EXPERIMENTAL
Intervention: Conservative therapy for mild incontinence
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conservative therapy for moderate incontinence
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Follow-up at 2 years for mild incontinence
Number of subjects: 150

Group type: COMPARATOR
Intervention: Follow-up at 2 years for moderate incontinence
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Responders for mild incontinence
Number of subjects: 150

Group type: COMPARATOR
Intervention: Responders for moderate incontinence
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Quality of life improvements
Number of subjects: 150
Study: 10875168

Group type: EXPERIMENTAL
Intervention: Quizzes for previewing frequently asked questions (FAQ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quizzes for previewing chapter outlines
Number of subjects: 0
Study: 9537132

Group type: EXPERIMENTAL
Intervention: Conjunctival autograft
Number of subjects: 59

Group type: COMPARATOR
Intervention: Topical mitomycin C (0.2 mg/ml, 0.02%)
Number of subjects: 59
Study: 8182273

Group type: EXPERIMENTAL
Intervention: Formalin‐inactivated, alum‐adjuvanted hepatitis A vaccine (VAQTA)
Number of subjects: 0
Study: 3802604

Group type: EXPERIMENTAL
Intervention: Sublingual nifedipine 10 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sublingual isosorbide dinitrate (ISDN) 5 mg
Number of subjects: 60
Study: 31238172

Group type: EXPERIMENTAL
Intervention: ADS Plus intervention providing family caregivers with support via education, referrals, and problem-solving techniques over 12 months, delivered on-site by existing ADS staff.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard Adult Day Services (ADS) without the embedded caregiver support program.
Number of subjects: 50
Study: 28468077

Group type: EXPERIMENTAL
Intervention: Jitai tablet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Jitai tablet plus buprenorphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26667089

Group type: EXPERIMENTAL
Intervention: Dipstick test results (negative/equivocal, 1+, ≥2+)
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Dipstick test results (1+) in normotensive women
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: P/Cr test
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Postpartum urine samples
Number of subjects: 1033
Study: 23774044

Group type: EXPERIMENTAL
Intervention: Myofascial treatment in the masseter and temporalis muscles
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham (placebo) intervention
Number of subjects: 48
Study: 21619574

Group type: EXPERIMENTAL
Intervention: Intensive training (3-5 sessions per week, session duration minimum 50 minutes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard training (3-5 sessions per week, session duration maximum 25 minutes)
Number of subjects: 0
Study: 19808138

Group type: EXPERIMENTAL
Intervention: Test formulation of levofloxacin 500 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Reference formulation of levofloxacin 500 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 26
Study: 17034283

Group type: EXPERIMENTAL
Intervention: Yunzhi-Danshen capsules (3.6 g Yunzhi and 1.4 g Dangshem daily for 16 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (12 capsules daily for 16 weeks)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Yunzhi-Danshen capsules
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 15073259

Group type: EXPERIMENTAL
Intervention: 0.01 mg rhTSH
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.03 mg rhTSH
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control groups (no rhTSH pretreatment)
Number of subjects: 36
Study: 11180306

Group type: EXPERIMENTAL
Intervention: Balanced designs using covariates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imbalance measure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random selection method from balanced designs
Number of subjects: 0
Study: 9416454

Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 47
Study: 8332693

Group type: EXPERIMENTAL
Intervention: Scamper technique
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Trait anxiety
Number of subjects: 52
Study: 2945811

Group type: EXPERIMENTAL
Intervention: Teicoplanin (0.2 g)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Vancomycin (1 g)
Number of subjects: 6
Study: 28805281

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg and Caffeine 100 mg
Number of subjects: 562

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 562

Group type: COMPARATOR
Intervention: Caffeine
Number of subjects: 562

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 562
Study: 27624487

Group type: EXPERIMENTAL
Intervention: Combined group (Anxiety and Depression)
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: Depression only group
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: Combined group
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: Internalizing symptoms
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: Symptoms of depression
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 915
Study: 24837773

Group type: EXPERIMENTAL
Intervention: First dose of MMR at 8 months
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: First dose of MMR at 12 months
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Both groups after first dose of MMR
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Both groups after second dose of MMR
Number of subjects: 280
Study: 22257994

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-based skin preparation solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: Iodine-based skin preparation solution
Number of subjects: 20
Study: 20483888

Group type: EXPERIMENTAL
Intervention: Electronic metronome without therapy but limited support (5-10 minutes instruction and on-demand telephone assistance) for four weeks (early group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Electronic metronome without therapy but limited support (5-10 minutes instruction and on-demand telephone assistance) for four weeks (late group)
Number of subjects: 42
Study: 17922612

Group type: EXPERIMENTAL
Intervention: Strontium ranelate (2 g/d)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 16002204

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) program, initiated before discharge, consisting of Kegel exercises.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no formal instruction in PFMT).
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Overall population (both groups).
Number of subjects: 300
Study: 11792137

Group type: EXPERIMENTAL
Intervention: tirofiban + heparin
Number of subjects: 1915

Group type: COMPARATOR
Intervention: heparin alone
Number of subjects: 1915

Group type: EXPERIMENTAL
Intervention: tirofiban
Number of subjects: 1915
Study: 10367823

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (1600 microg/d for 21 days)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo (identical to budesonide, for 21 days)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 188
Study: 7739681

Group type: EXPERIMENTAL
Intervention: 3 million units of interferon alfa-2b given subcutaneously three times a week for 18 months (group 1)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: 1 million units of interferon alfa-2b three times a week for 12 months (group 2)
Number of subjects: 303

Group type: COMPARATOR
Intervention: No further treatment (group 3)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: 3 million units of interferon alfa-2b given three times a week for 18 months (group 1)
Number of subjects: 303
Study: 2199866

Group type: EXPERIMENTAL
Intervention: Cefazolin (2 g intravenously)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Cefotetan (2 g intravenously)
Number of subjects: 377
Study: 7028047

Group type: EXPERIMENTAL
Intervention: Ciclopiroxolamine cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clotrimazole cream
Number of subjects: 0
Study: 30887679

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic partial nephrectomy (RAPN)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Laparoscopic partial nephrectomy (LPN)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Both RAPN and LPN
Number of subjects: 142
Study: 30343592

Group type: EXPERIMENTAL
Intervention: Bipolar TURBT
Number of subjects: 160

Group type: COMPARATOR
Intervention: Monopolar TURBT
Number of subjects: 160
Study: 26325026

Group type: EXPERIMENTAL
Intervention: CogniPlus method with dynamic balance training (20 cognitive training sessions twice per week for 10 weeks)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CogniPlus method with dynamic balance training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Balance training alone (same duration and frequency as experimental group)
Number of subjects: 80
Study: 26905701

Group type: EXPERIMENTAL
Intervention: High incision at upper part of lower segment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Traditional lower segment incision
Number of subjects: 200
Study: 21457353

Group type: EXPERIMENTAL
Intervention: Autologous bone (AB) chips
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Ossix membrane (OM)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Combination of AB chips and OM
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 92
Study: 20649896

Group type: EXPERIMENTAL
Intervention: Fluid warmed using a warming cabinet for at least 8 hours
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Fluid warmed using an in-line warming device
Number of subjects: 76

Group type: COMPARATOR
Intervention: Fluid at room temperature
Number of subjects: 76
Study: 17666481

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 339
Study: 15033676

Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-5-FU chemotherapy (cis/carboplatin, anthracycline, cyclophosphamide)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU) with glyceroltrinitrate pre-treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-5-FU chemotherapy
Number of subjects: 60
Study: 11839841

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Number of subjects: 0

Group type: COMPARATOR
Intervention: MRI metrics (new enhancing lesions, percentage change of T2 lesion volume, composite MRI score)
Number of subjects: 0
Study: 10424691

Group type: EXPERIMENTAL
Intervention: High-intensity noise deviant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced noise intensity
Number of subjects: 0
Study: 7749824

Group type: EXPERIMENTAL
Intervention: Fish oil (2.4 g daily)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Fish oil with vitamin E (2.4 g daily)
Number of subjects: 33
Study: 2261209

Group type: EXPERIMENTAL
Intervention: Intravenous administration of Idarubicin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral administration of Idarubicin under non-fasting conditions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Idarubicinol (metabolite)
Number of subjects: 10
Study: 376027

Group type: EXPERIMENTAL
Intervention: Intestinal perfusion method
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard method (not explicitly mentioned)
Number of subjects: 40
Study: 31068015

Group type: EXPERIMENTAL
Intervention: Adjunctive chronotype-based bright light therapy (30 minutes a day for 3 weeks, illuminance: 4246 lux, irradiance: 1802.81 µW.cm‐2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with multimodal psychiatric treatment
Number of subjects: 0
Study: 28374211

Group type: EXPERIMENTAL
Intervention: FITNET (Facebook-based physical activity intervention)
Number of subjects: 85

Group type: COMPARATOR
Intervention: SC (self-help comparison condition)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 85
Study: 25823522

Group type: EXPERIMENTAL
Intervention: Thawed universal donor (UD) plasma
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Blood group A plasma
Number of subjects: 680

Group type: COMPARATOR
Intervention: Thawed AB plasma
Number of subjects: 680
Study: 24022799

Group type: EXPERIMENTAL
Intervention: Misleading narrative
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control narrative
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Delayed test (2 weeks after viewing)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Self-report of greater distress
Number of subjects: 93
Study: 21872473

Group type: EXPERIMENTAL
Intervention: High custom made orthopaedic shoe
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal shoes
Number of subjects: 19